"Developing TB Vaccines is Hard"

Although BCG vaccine remains useful for neonatal vaccination in human populations, its inability to prevent pulmonary TB in adults has inspired a decades-long effort to discover new more effective TB vaccines for human disease. There has been progress in many aspects of TB vaccine development but many challenges remain. In this presentation, successes and failures in TB vaccine development, with an emphasis on the knowledge that has been gained over the past decade, will be discussed. The importance of a collaborative iterative approach which integrates new technologies into TB vaccine development will be emphasized. While more basic research on the immunopathogenesis of TB is needed to guide the vaccine development effort, this should also be balanced with empirical approaches to vaccine production and clinical assessment. Safe and effective new TB vaccines are a critical tool needed to stem the current rise in drug resistant TB and the global incidence of this ancient disease worldwide.

Friday, November 21st
11:00am
136 DeBartolo Hall